stockportfolio.pro
MoonLake Immunotherapeutics (MLTX)
Healthcare · Biotechnology · NasdaqCM
MoonLake Immunotherapeutics revenue & earnings — last 5 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — |
| Net income | $-4.54M | $-49.97M | $-36.01M | $-118.94M | $-227.32M |
| Net margin | — | — | — | — | — |
Source: MoonLake Immunotherapeutics SEC filings (10-K).
Explore 5 years of MoonLake Immunotherapeutics financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MLTX in your portfolio →
MoonLake Immunotherapeutics financial history by metric
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics — frequently asked questions
What is MoonLake Immunotherapeutics's revenue?
MoonLake Immunotherapeutics (MLTX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is MoonLake Immunotherapeutics profitable?
No — MLTX reported a net loss of $-227.32M in fiscal 2025.
What is MLTX's P/E ratio?
MoonLake Immunotherapeutics trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does MoonLake Immunotherapeutics have?
As of fiscal year 2025, MLTX carried roughly $74.10M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is MoonLake Immunotherapeutics's market cap?
MoonLake Immunotherapeutics (MLTX) has a market capitalization of about $1.30B, based on the latest data in our nightly-refreshed cache.
When does MoonLake Immunotherapeutics's fiscal year end?
MLTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from MoonLake Immunotherapeutics's official SEC filings (10-K and 10-Q), covering 5 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.